Overview

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.

Phase:

PHASE2

Details

Lead Sponsor:

Institut fr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Treatments:

Bevacizumab
HMPL-013
tislelizumab
trifluridine tipiracil drug combination